Virucidal benefits of povidone-iodine use on the ocular surface: a review.
epidemiology
microbiology
ocular surface
public health
treatment other
Journal
BMJ open ophthalmology
ISSN: 2397-3269
Titre abrégé: BMJ Open Ophthalmol
Pays: England
ID NLM: 101714806
Informations de publication
Date de publication:
2020
2020
Historique:
received:
12
05
2020
revised:
23
07
2020
accepted:
28
07
2020
entrez:
21
8
2020
pubmed:
21
8
2020
medline:
21
8
2020
Statut:
epublish
Résumé
Povidone-iodine (PVI) preparations are well known for their microbicidal effect. In ophthalmology, PVI is commonly used to sterilise the ocular surface prior to surgical procedures. It is also used uncommonly as treatment for adenoviral conjunctivitis, yet the virucidal benefits of PVI have not been clearly documented in existing clinical management guidelines for ocular surface conditions. The COVID-19 pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, has challenged traditional healthcare systems. The morbidity and mortality of this highly contagious disease have resulted in fatalities among healthcare workers, including ophthalmologists. The SARS-CoV-2 virus has been identified on conjunctival testing, a potential source of contagious infection which may be unrecognised in asymptomatic carriers. Concern has been raised that ocular procedures may be 'aerosol-generating' and the additional wearing of personal protective equipment has been recommended to protect operating theatre staff. This literature review demonstrates that PVI has a broad virucidal activity, including against coronaviruses. It is already used perioperatively as standard of ophthalmic care and has been shown clinically to be effective against adenoviruses on the ocular surface. The current surgical practice of application of 5%-10% PVI applied periocularly for 3 min seems to provide an adequate effective reduction in the patient's ocular surface viral load. The virucidal benefits of routine PVI use should be included in ophthalmology guidelines regarding safe ocular surgery protocols.
Identifiants
pubmed: 32818151
doi: 10.1136/bmjophth-2020-000509
pii: bmjophth-2020-000509
pmc: PMC7406023
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e000509Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Int J Surg. 2017 Aug;44:260-268
pubmed: 28648795
Int J Ophthalmol. 2019 Sep 18;12(9):1420-1425
pubmed: 31544037
In Vivo. 1999 May-Jun;13(3):239-41
pubmed: 10459499
Dermatology. 2006;212 Suppl 1:115-8
pubmed: 16490988
Am J Ophthalmol. 1990 Mar 15;109(3):329-33
pubmed: 2155533
Am J Ophthalmol. 2016 Oct;170:68-74
pubmed: 27448925
Infect Dis Ther. 2015 Dec;4(4):491-501
pubmed: 26416214
Retina. 2016 Jul;36(7):1349-56
pubmed: 26655622
Br J Ophthalmol. 2003 Feb;87(2):163-7
pubmed: 12543744
Nippon Ganka Gakkai Zasshi. 2007 May;111(5):384-90
pubmed: 17536497
J Clin Invest. 2003 Jun;111(11):1605-9
pubmed: 12782660
Acta Ophthalmol. 2017 Dec;95(8):e686-e692
pubmed: 28342227
J Acquir Immune Defic Syndr (1988). 1989;2(1):16-20
pubmed: 2465403
Adv Ther. 2009 Aug;26(8):776-83
pubmed: 19756415
Ophthalmology. 1991 Dec;98(12):1769-75
pubmed: 1775308
Kansenshogaku Zasshi. 1995 May;69(5):532-8
pubmed: 7602186
Dermatology. 2002;204 Suppl 1:92-5
pubmed: 12011529
Am J Ophthalmol. 2018 Oct;194:7-15
pubmed: 29787732
Sex Transm Dis. 1995 Jan-Feb;22(1):22-4
pubmed: 7709321
Emerg Infect Dis. 2005 Aug;11(8):1225-9
pubmed: 16102311
Virol J. 2009 Aug 13;6:124
pubmed: 19678928
Antiviral Res. 2002 May;54(2):89-97
pubmed: 12062394
J Hosp Infect. 2007 Mar;65(3):264-70
pubmed: 17241695
Cutan Ocul Toxicol. 2015 Mar;34(1):12-5
pubmed: 24678746
Graefes Arch Clin Exp Ophthalmol. 2020 Aug;258(8):1831-1833
pubmed: 32314033
Clin Ophthalmol. 2020 Mar 17;14:837-852
pubmed: 32256043
Dermatology. 2002;204 Suppl 1:114-20
pubmed: 12011534
Exp Anim. 2012;61(1):35-40
pubmed: 22293670
Infect Control. 1987 Oct;8(10):412-4
pubmed: 3667119
J Hosp Infect. 2004 May;57(1):67-72
pubmed: 15142718
Curr Eye Res. 2015 Sep;40(9):870-7
pubmed: 25310347
J Ocul Pharmacol Ther. 2019 Mar;35(2):132-136
pubmed: 30589605
J Hosp Infect. 2020 Mar;104(3):246-251
pubmed: 32035997
J Cataract Refract Surg. 2009 Dec;35(12):2109-14
pubmed: 19969216
Ophthalmic Res. 2000 Mar-Jun;32(2-3):118-25
pubmed: 10754445
Ocul Immunol Inflamm. 2020 Apr 2;28(3):391-395
pubmed: 32175797
Infect Dis Ther. 2019 Dec;8(4):581-593
pubmed: 31414403
Dermatology. 1997;195 Suppl 2:29-35
pubmed: 9403252
Klin Monbl Augenheilkd. 1990 Sep;197(3):214-7
pubmed: 1701507
Clin Ophthalmol. 2019 Mar 21;13:535-544
pubmed: 30962674
Dermatology. 1997;195 Suppl 2:111-6
pubmed: 9403268
Klin Monbl Augenheilkd. 2006 May;223(5):349-52
pubmed: 16705502
J Cataract Refract Surg. 2017 Jun;43(6):861-862
pubmed: 28732632
Br J Ophthalmol. 2004 Jul;88(7):861-3
pubmed: 15205225
J Ocul Pharmacol Ther. 2012 Feb;28(1):53-8
pubmed: 21916618
BMC Infect Dis. 2015 Sep 17;15:375
pubmed: 26381737
Ocul Surf. 2019 Oct;17(4):828-832
pubmed: 31401340
Infect Dis Ther. 2018 Jun;7(2):249-259
pubmed: 29633177
Curr Opin Ophthalmol. 2018 Jan;29(1):19-32
pubmed: 28984794
Eye (Lond). 2003 Apr;17(3):356-63
pubmed: 12724699
J Pak Med Assoc. 2016 Aug;66(8):968-70
pubmed: 27524529
Lett Appl Microbiol. 2010 Aug;51(2):158-63
pubmed: 20536707
Br J Ophthalmol. 2009 Jan;93(1):3
pubmed: 19098040
Biocontrol Sci. 2016;21(1):21-7
pubmed: 27009506
Retina. 2014 Dec;34 Suppl 12:S1-S18
pubmed: 25489719
Anesth Analg. 2020 Jul;131(1):37-42
pubmed: 32217947
Invest Ophthalmol Vis Sci. 2011 Jan 21;52(1):339-44
pubmed: 20702820
Dermatology. 2006;212 Suppl 1:119-23
pubmed: 16490989